Litigation Details for Genentech, Inc. v. Pfizer, Inc. (D. Del. 2017)

« Back to Dashboard

Genentech, Inc. v. Pfizer, Inc. (D. Del. 2017)

Docket		Date Filed	2017-11-17
Court	District Court, D. Delaware	Date Terminated	2018-12-04
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	8,460,895; 8,512,983; 8,574,869; 9,487,809; 9,714,293
Link to Docket	External link to docket

Biologic Drugs cited in Genentech, Inc. v. Pfizer, Inc.

Details for Genentech, Inc. v. Pfizer, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-11-17				External link to document

Genentech v. Pfizer, 1:17-cv-01672: Litigation Summary and Patent Analysis

Last updated: August 22, 2026

Genentech, Inc. v. Pfizer, Inc., No. 1:17-cv-01672, was a Delaware patent dispute over Pfizer’s trastuzumab biosimilar, PF-05280014, later marketed in the United States as Trazimera. Genentech asserted Herceptin-related patents under the Biologics Price Competition and Innovation Act. The case ended through a settlement rather than a final infringement judgment. Pfizer received FDA approval for Trazimera in March 2019 and subsequently commercialized the product in the United States under the negotiated resolution.[1][2]

What drug and FDA pathway were involved in Genentech v. Pfizer?

The case involved trastuzumab, the monoclonal antibody marketed by Genentech as Herceptin.

Item	Details
Reference product	Herceptin
Active ingredient	Trastuzumab
Reference-product sponsor	Genentech, a Roche group company
Biosimilar developer	Pfizer
Pfizer development code	PF-05280014
U.S. brand	Trazimera
FDA pathway	Section 351(k) biosimilar application
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-01672
Legal framework	BPCIA patent-exchange and infringement provisions
Outcome	Settlement and case termination

Trazimera was approved as a biosimilar to Herceptin for the same principal oncology indications, including HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal-junction cancer.[1]

The case was not an abbreviated new drug application dispute. Trastuzumab is a biologic, so Pfizer proceeded through the FDA’s biosimilar pathway rather than the Hatch-Waxman generic-drug pathway.

What patents protected Herceptin and trastuzumab?

Genentech’s patent estate covered several distinct layers:

1. The trastuzumab antibody and related antibody technology.
2. Cell lines and recombinant production methods.
3. Formulation and stability characteristics.
4. Methods of treating HER2-positive cancers.
5. Dosing and administration regimens.
6. Manufacturing and analytical processes.

The core composition-of-matter protection for trastuzumab was associated with U.S. Patent No. 6,627,196. Other Herceptin-related patents covered antibody production, formulations, treatment methods and dosing technologies. The asserted portfolio in the Pfizer litigation was broader than a single composition patent and reflected Genentech’s effort to delay biosimilar entry after primary molecule protection approached expiration.[3]

Were all Herceptin patents composition patents?

No. The estate included different patent categories with different commercial relevance.

Patent category	Commercial purpose	Typical biosimilar exposure
Antibody composition	Protects the antibody or related sequence	Highest risk if valid and infringed
Cell culture and manufacturing	Protects production methods	Depends on Pfizer’s process
Formulation	Protects liquid or concentrated drug presentation	Relevant to the marketed dosage form
Method of treatment	Protects use in a defined patient population	Often subject to carve-outs or label strategies
Dosing regimen	Protects administration schedule or loading dose	Can affect label design and prescribing
Analytical or purification method	Protects process controls or purification	May create manufacturing risk without blocking the label

The distinction mattered because Pfizer could potentially avoid some method-of-use claims through a restricted label or “skinny label,” while process claims required an assessment of Pfizer’s manufacturing operations.

How did the BPCIA litigation process apply?

Pfizer’s filing of a biosimilar application triggered the BPCIA patent-information exchange. Genentech received information concerning the product and manufacturing process, and the parties exchanged patent positions before Genentech filed suit.

The BPCIA process generally involved:

• Pfizer’s disclosure of the biosimilar application and manufacturing information.
• Genentech’s identification of patents it considered relevant.
• Pfizer’s validity, enforceability and infringement positions.
• Negotiation over patents for immediate litigation.
• Genentech’s complaint in the District of Delaware.
• Later resolution of the patent dispute through settlement.

The BPCIA did not automatically require Pfizer to wait until every Herceptin-related patent expired. The timing depended on patent validity, infringement exposure, settlement terms and any remaining regulatory exclusivity.

What was the litigation status and final outcome?

The case was resolved by settlement. There was no reported final trial judgment invalidating or upholding every asserted patent, and no publicly reported damages verdict.

The settlement allowed Pfizer to proceed with Trazimera commercialization after the agreed entry date. Because the agreement was confidential, the public record does not provide a complete patent-by-patent allocation of:

• Which claims Genentech considered enforceable.
• Which patents Pfizer agreed not to challenge.
• Whether Pfizer paid a settlement amount.
• The precise launch date permitted under the agreement.
• Any restrictions on future indications or manufacturing changes.

The practical result was a negotiated biosimilar entry rather than a judicial test of the full Herceptin patent estate.

When did Herceptin lose exclusivity?

Herceptin lost effective market exclusivity in stages rather than on one date.

Exclusivity layer	Approximate significance
FDA biologic exclusivity	Expired before Trazimera approval
Core antibody patent protection	Reached expiration near the start of the U.S. biosimilar launch period
Secondary formulation and method patents	Created litigation and timing risk beyond the core patent
Settlement protection	Controlled Pfizer’s commercial entry timing
Biosimilar competition	Began in the United States in 2019

The FDA’s 12-year reference-product exclusivity for biologics did not prevent approval of Trazimera by 2019. The remaining dispute centered primarily on patent rights and the negotiated launch timetable.[1]

Herceptin’s core patent protection was therefore less important than the complete portfolio. Even after the principal molecule patent expired or approached expiration, formulation, dosing, treatment and process patents could support litigation.

What was the Orange Book status of Herceptin?

Herceptin is not listed in the FDA Orange Book because it is a biologic rather than a conventional small-molecule drug.

The relevant FDA publication is the Purple Book, which identifies licensed biological reference products and biosimilars. Patent disputes involving biologics are handled under the BPCIA, not through the Orange Book patent-listing and Paragraph IV certification system used for small-molecule products.[4]

Did Pfizer file a Paragraph IV challenge?

No traditional Paragraph IV certification applied to this case. Pfizer’s challenge proceeded through the BPCIA patent-exchange framework.

The commercial effect was similar to a Paragraph IV case in one respect: Pfizer challenged the ability of Genentech’s patents to block biosimilar entry. The procedural mechanics differed materially.

Which patents created the largest generic or biosimilar entry risk?

The highest-value risks were likely concentrated in four groups.

Core trastuzumab patents

These patents created the clearest blocking risk but were also the most likely to face expiration before or around biosimilar commercialization.

Formulation patents

Formulation claims could cover the commercial product rather than the antibody alone. Their value depended on whether Pfizer’s Trazimera formulation used the same or an equivalent protected formulation.

Method-of-use patents

Genentech could assert treatment claims directed to HER2-positive cancer, combination therapy or patient selection. Pfizer could reduce exposure through prescribing-information carve-outs where permitted by FDA labeling rules.

Manufacturing patents

Manufacturing claims can create substantial risk because biosimilar applicants must demonstrate similarity while maintaining proprietary production processes. A manufacturing patent can remain relevant even if the biosimilar label omits a patented indication.

For business purposes, the case demonstrates why a biologic patent analysis must compare the reference product’s patent portfolio against the biosimilar’s actual formulation, manufacturing process and proposed label. Patent expiration alone does not determine entry risk.

How strong was Genentech’s patent estate?

Genentech’s estate was commercially strong but time-limited.

Strengths

• Multiple patent categories reduced dependence on one composition patent.
• Herceptin generated a large commercial incentive to delay or control biosimilar entry.
• Method and formulation claims could extend litigation beyond primary molecule protection.
• The BPCIA process gave Genentech early access to information about Pfizer’s product and manufacturing process.
• A settlement preserved negotiated control over market entry.

Weaknesses

• The core biologic and antibody-related rights were approaching expiration.
• Secondary patents faced validity and written-description challenges common in biologic litigation.
• Method-of-use claims could be narrowed through label carve-outs.
• Manufacturing claims required proof that Pfizer’s confidential process practiced the patented limitations.
• Trazimera had FDA approval, creating strong commercial pressure to resolve the dispute.

The settlement indicates that both parties faced material litigation risk. It does not establish that Genentech’s patents were invalid, nor does it establish that Pfizer’s product infringed.

How did Trazimera compare with competing trastuzumab biosimilars?

Trazimera entered a market that included other trastuzumab biosimilars approved or developed for the United States.

Product	Sponsor	U.S. status
Herceptin	Genentech/Roche	Reference product
Trazimera	Pfizer	FDA-approved biosimilar
Kanjinti	Amgen/Allergan	FDA-approved biosimilar
Ogivri	Mylan/Biocon	FDA-approved biosimilar
Herzuma	Celltrion/Teva	FDA-approved biosimilar

The competitive outcome depended on more than FDA approval. Entry dates, payer contracting, oncology-provider familiarity, interchangeability status, supply reliability and net pricing affected market share.

Trazimera did not receive an interchangeable designation. Interchangeability was not required for physician-administered oncology products to compete, but it could affect substitution practices and payer policies.

What revenue exposure did the litigation create?

Herceptin was one of Roche’s largest products before biosimilar competition. Roche reported multi-billion-dollar annual Herceptin sales globally before the U.S. and international erosion period.[5]

The litigation therefore affected:

• Genentech and Roche’s U.S. trastuzumab revenue.
• Pfizer’s ability to monetize its biosimilar investment.
• Hospital and oncology-practice acquisition costs.
• Payer savings from biosimilar competition.
• The timing of revenue loss from the reference product.
• The value of later-generation HER2 products, including pertuzumab combinations and subcutaneous delivery products.

For Genentech, a delayed biosimilar launch preserved additional Herceptin revenue. For Pfizer, an earlier launch improved the payback period for clinical development, manufacturing scale-up and commercial distribution.

Did the case involve licensing deals or a public settlement agreement?

The docket reflects a settlement resolving the litigation, but the material commercial terms were not publicly disclosed in a complete agreement.

No public license appears to have converted Pfizer into a licensee with unrestricted immediate entry. The practical structure was a settlement-based launch arrangement tied to the parties’ resolution of patent claims.

This differs from a public cross-license or technology-transfer agreement. The case should therefore be classified as a confidential patent settlement involving biosimilar market entry, not as a publicly documented manufacturing license.

What generic launch scenarios resulted from the settlement?

Three launch scenarios were commercially possible during the case:

Scenario	Effect on Pfizer	Effect on Genentech
Immediate launch after approval	Rapid Trazimera revenue; severe Herceptin erosion	Maximum near-term revenue loss
Delayed launch under settlement	Predictable entry date and reduced litigation cost	Additional protected revenue period
Continued litigation to judgment	Potential complete victory or invalidation	High cost and binary outcome

The settlement selected the middle path. Pfizer obtained a defined route to commercialization, while Genentech avoided the uncertainty of a trial and preserved a period of additional market protection.

What geographic coverage did the case have?

The action was a U.S. federal patent case and directly addressed U.S. market entry. It did not resolve patent rights in Europe, Japan, Canada or other jurisdictions.

Global trastuzumab biosimilar entry proceeded through separate national and regional legal systems. A U.S. settlement could not by itself grant Pfizer freedom to commercialize Trazimera in foreign markets.

What manufacturing and intellectual-property barriers remained?

Even after settlement, Pfizer faced several barriers:

• FDA requirements for continued biosimilarity compliance.
• Scale-up and supply reliability for a complex monoclonal antibody.
• Validation of commercial manufacturing sites.
• Immunogenicity and analytical comparability controls.
• Patent exposure from future process changes.
• Separate patent rights in foreign markets.
• Payer and hospital formulary adoption.
• Competition from other trastuzumab biosimilars.

Genentech retained the ability to enforce patents outside the settled claims if Pfizer changed the product, manufacturing process or label in a way that created a new infringement issue.

Key Takeaways

• Genentech v. Pfizer, 1:17-cv-01672, concerned Pfizer’s trastuzumab biosimilar PF-05280014, later branded Trazimera.
• The case proceeded under the BPCIA, not the Hatch-Waxman Paragraph IV framework.
• Genentech relied on a portfolio covering trastuzumab technology, formulation, treatment methods and manufacturing.
• Trazimera received FDA approval in March 2019.
• The litigation ended in settlement rather than a final merits judgment.
• The settlement enabled Pfizer’s U.S. commercial entry while giving Genentech a negotiated period of additional market protection.
• Herceptin has no Orange Book listing; biologic patent and biosimilar information is analyzed through the BPCIA and Purple Book framework.
• The case illustrates the commercial importance of secondary biologic patents after core molecule protection approaches expiration.

FAQs About Genentech v. Pfizer and Trazimera

Was Genentech v. Pfizer a biosimilar patent lawsuit?

Yes. It was a BPCIA lawsuit concerning Pfizer’s proposed trastuzumab biosimilar, PF-05280014, later marketed as Trazimera.

Did Pfizer win the patent case?

Neither party obtained a reported final merits victory. The case was resolved through settlement, allowing Pfizer to commercialize Trazimera under agreed conditions.

Is Trazimera interchangeable with Herceptin?

The FDA approved Trazimera as a biosimilar to Herceptin, but it did not receive an interchangeable designation at approval.

Does Herceptin have Orange Book patents?

No. Herceptin is a biologic, so its relevant regulatory and patent framework is the Purple Book and BPCIA rather than the Orange Book.

Did the settlement eliminate all Genentech patent risk for Trazimera?

No public record establishes unrestricted freedom to operate for every future Trazimera formulation, manufacturing process, indication or geographic market. The settlement resolved the identified case and its asserted claims.

References

1. U.S. Food and Drug Administration. (2019, March 11). Trazimera (trastuzumab-qyyp) approval letter and prescribing information. https://www.fda.gov
2. U.S. District Court for the District of Delaware. (2017). Genentech, Inc. v. Pfizer, Inc., No. 1:17-cv-01672. PACER docket.
3. U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,627,196: Humanized anti-ErbB2 antibodies.
4. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
5. Roche Holding Ltd. (2019). Annual report 2018. Roche.